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Abstract
Introduction—Polymorphic alleles in the human genome have been identified as affecting
numerous drug responses. Currently, genotyping of all patients before starting a drug regimen is
impractical. Since many polymorphisms occur at varying rates in different racial groups, we
investigated whether a patient's race could predict presence of drug-relevant genetic variants well
enough to be used as a substitute for individual genotyping.
Methods—We performed hierarchical clustering and principal components analysis on tagSNPs
from three pathways (irinotecan, 5-fluorouracil and insulin) across 270 individuals from four racial
groups available from the International HapMap Project.
Results—For the drug pathways, irinotecan and 5-fluorouracil, individuals from each race were
widely dispersed, although several subclusters consisted entirely of individuals from a single racial
group. Principal components analysis confirmed race was not a major contributor to the SNP data
variance. Interestingly, individuals tended to cluster more by race across the endogenous insulin
signaling pathway SNPs.
Conclusions—Most genetic variation was determined by individual variation, not racial grouping,
indicating race is not adequate as a surrogate to individualized therapy.
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One of the most difficult challenges in biomedical research has been defining the mechanisms
underlying the interindividual variations in drug response. Among the many demographic (e.g.,
gender and age) and biochemical (e.g., renal function and liver function) factors often evaluated
for influence on drug effects, one of the most commonly included variants is self-declared
patient race. Racial differences have been observed for response to β-blockers, mydriatics and
opioid pain relievers, among other medications [1-8]. In fact, the US FDA has approved drugs
with prescribing guidelines targeted towards a specific racial group [9]. BiDil, a combination
of hydralazine and isosorbide dinitrate, was approved for treating heart failure in African-
American patients, after results from the African-American Heart Failure Trial (A-HeFT)
supported clinical benefit from the drug [10,101].
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In addition to demographic and biochemical factors influencing drug response, variants in
genes involved in drug metabolism, membrane transport and cellular targets have also been
identified. The US FDA has begun including genetic variation in prescribing information when
it has been shown to identify elevated risk for toxicity or differential efficacy. Initial examples
have focused on single genes, in which variants lead to altered protein function or transcription.
Recently, the FDA has made changes to the package insert that support genetic testing of
specific genes for all patients prior to prescribing warfarin (CYP2C9 and VKORC1) and for
patients of Asian descent before taking carbamazepine (HLA-B*1502) [102,103]. These
represent initial examples for what will likely become a common approach to
pharmacogenomics: the use of heterogeneity in genes associated with molecular pathways to
predict drug effects.
With the completion of the human genome sequencing project, vast amounts of genetic data
have become readily accessible from online databases, such as the International HapMap
Project [104]. HapMap offers SNP analysis from 270 individuals from four ethnic groups: the
Yoruba from Ibadan, Nigeria (YRI); Japanese from Tokyo, Japan (JPT); Han Chinese from
Beijing, China (CHB); and CEPH Caucasian from Utah, of Northern and Western European
descent (CEU). The HapMap project was created to assist researchers in discovering genetic
markers that predispose individuals for diseases, such as cancer, stroke and depression, or affect
an individual's response to pharmaceutical treatment [105].
Most specific genetic variants occur in all human populations, but at varying rates. Thus, the
availability of large numbers of variants begins to allow the discernment of an individual's
racial group. We asked if the reverse is also true: if we know a patient's self-identified race,
can we predict genotype at specific, drug-relevant markers? We were not seeking ancestry
informative markers. Instead, we were attempting to determine if self-identified patient race
has any potential utility as a predictive factor prior to prescribing medications and, therefore,
allow for better patient care by improving efficacy and lowering toxicity rates.
We recognize that the term `race' is largely a social construction, and its usage can raise a
variety of socio-ethical concerns [11-15]. Furthermore, the definition is apt to evolve and
change over time, making long-term research and recommendations difficult [16]. However,
in the absence of a better term, we chose to use `race' to signify the diverse population from
within a specific geographic locale (Ibadan, Nigeria; Tokyo; Japan; Beijing; China; or Utah,
USA), as chosen by the International HapMap Project [17].
Using data from individuals in the four populations available in HapMap, we examined SNPs
in genes from two drug pathways, irinotecan and 5-fluorouracil (5-FU). The genes included in
the irinotecan pathway have little endogenous biological interaction with each other, outside
of irinotecan processing, while the 5-FU pathway genes include both 5-FU specific genes (e.g.,
MTHFR and DHFR), as well as genes that interact in several endogenous pathways (e.g.,
pyrimidine biochemistry). In addition, a parallel analysis was performed to compare the results
obtained from the drug pathways with a collection of random SNPs and an entirely endogenous
pathway (insulin signaling). Using hierarchical clustering and principal components analysis
(PCA), we assessed whether race, and the attendant race-dependent genetic variation, is
sufficient to act as a surrogate for genotyping individuals. Although there is some clustering
within racial groups for the genes of the drug pathways, the majority of the genetic variation
between individuals genotyped by the International HapMap Project is due to individual
variation, not race.
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Genes involved in the pharmacokinetics and pharmacodynamics of irinotecan (n = 13) and 5-
FU (n = 21) were identified using the drug pathway diagrams on the PharmGKB website
[106]. Irinotecan and 5-FU were chosen because the metabolic pathways involved in
processing the drugs have relatively clear delineation. Ten genes involved in insulin signaling
were chosen from the diagram on the National Cancer Institute/Nature Pathway Interaction
Database [107]. Insulin signaling was chosen to represent a biological pathway containing a
similar number of genes to the irinotecan and 5-FU pathways. A total of 362 SNPs were
randomly chosen from the Affymetrix 500K SNP chip to use as a control. Supplementary Table
1, available online [108] lists all of the genes and SNPs used in this analysis.
SNP genotype data was downloaded for all of the individuals from the four populations from
HapMap release NCBI build 35, dbSNP b125 [104]. The four HapMap populations were
included in the analysis: YRI, JPT, CHB and CEU. TagSNPs were chosen for each population
using Haploview (version 3.32), using a minimum minor allele frequency (MAF) of 10%, a
haplotype frequency of 10%, and an r2 threshold of 0.8. The tagSNPs from each population
were merged to generate the list of tagSNPs for each gene. This resulted in 173 SNPs covering
13 genes in the irinotecan pathway, 362 SNPs covering 21 genes in the 5-FU pathway and 172
SNPs covering ten genes in the insulin signaling pathway. The genotype frequency for all of
the SNPs used in this study is available on the HapMap website [104].
For each dataset (irinotecan pathway, 5-FU pathway, insulin signaling pathway, random
SNPs), the genotype data were transformed to numerical values for the purpose of clustering.
Genotypes for individuals were converted to 1 (reference allele homozygous), 0 (heterozygous)
or -1 (nonreference allele homozygous). The reference allele was determined from HapMap.
Any missing data was left blank. For each dataset, we performed hierarchical clustering on the
individuals and SNPs. Clustering was performed using Eisen's cluster program [18], using
uncentered correlation and complete linkage clustering. The clusters were viewed using Java
TreeView (version 1.1.0). PCA was performed for each data set using the `prcomp' algorithm
in R (version 2.4.1). Before running the PCA, missing data were imputed using a k-nearest
neighbor approach (k = 10). The resulting heat maps from the cluster analysis and the results
of the PCA across the first three principal components are available in Supplemental File 2,
can be found online [108].
Results
Using genotype data from the HapMap project, we examined the genetic groupings among
individuals in all four populations (YRI, JPT, CHB and CEU; n = 270) across the irinotecan
and 5-FU pathway genes. The genes in the irinotecan pathway come from many different
functional classes and have little endogenous interaction. In total, 173 tagSNPs from 13 genes
involved in irinotecan cell membrane transport and metabolism were analyzed. Hierarchical
clustering performed to examine the similarities in genotypes across the irinotecan pathway
demonstrated that race contributed little to the separation of individuals (Figure 1A).
Subclusters were relatively narrow, and individuals of different race were intermingled,
although a subcluster consisting of over 60% of the individuals in the YRI population was
identifiable. Individuals from the CHB and JPT populations were intermingled, while small
clusters of CEU individuals were scattered throughout the CHB/JPT, and among the YRI. We
also performed PCA for the irinotecan pathway genes to determine how much of the variance
of the SNP data could be attributed to race. Principal component (PC)#1 accounted for 39%
of the variance in the data, but failed to separate individuals on the basis of race (Figure 2A).
In fact, individuals of all races were found to be completely overlapping in PC#1, in agreement
with the hierarchical clustering analysis. However, by plotting PC#2 (14% of variance) against
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PC#3 (7% of variance), the YRI individuals tended to separate themselves from the other three
populations, but the CEU individuals still significantly overlapped with the CHB/JPT
individuals (Figure 2E).
The 5-FU pathway combines genes from several endogenous pathways into an artificial drug-
processing pathway. We analyzed 362 tagSNPs, encompassing 21 genes involved in 5-FU
catabolism, anabolism and activity. Hierarchical clustering generated five predominant clusters
of individuals (Figure 1B). In general, individual genotypes across the 5-FU pathway
influenced the clustering more than race, although a few subclusters consisting of individuals
from a single population were present in the data. Over 70% of the YRI were located in a single
subcluster, whose individuals were most similar to a subcluster consisting of JPT and CHB
individuals. Another prominent subcluster consisted of approximately 50% of the CEU, along
with 20% of the YRI individuals. PCA indicated no clear race differences across PC#1, which
accounted for 45% of the variance within the data (Figure 2B). However, the YRI completely
separated from the other populations across PC#2, which accounted for 7% of the variance.
Additionally, PC#3 separated the CEU individuals from the JPT/CHB mixture, accounting for
4% of the variance. Plotting the individuals across PC#2 and PC#3 almost totally separated
them into three distinct groups: YRI, CEU and the JPT/CHB mixture (Figure 2F).
We were surprised that race was not the primary contributor to the variance observed in the
hierarchical clustering and PCA results. To ensure we had a sufficient number of SNPs to
perform the analysis properly, we selected 362 SNPs at random from the Affymetrix 500K
SNP chip and performed the same hierarchical clustering and PCA. We found that individuals
clustered exclusively with members of the same racial group (although the CHB and JPT
populations overlapped entirely) across the 362 random SNPs (Figure 1D). Similarly, PC#1,
which accounted for 51% of the variance, mostly separated the YRI from the other three
populations (Figure 2D). As was seen with the 5-FU pathway analysis, the YRI were
completely isolated across PC#2 (7% of variance), while the CEU were separated from the
other groups across PC#3 (3% of variance). Again, plotting PC#2 against PC#3 separated the
YRI, CEU and CHB/JPT mixture into three distinct populations (Figure 2H). The complete
separation of the populations is consistent with recently published findings from Rosenberg
et al., who found that by using a sufficient number of genetic markers, sampled individuals
can be separated into distinct genetic clusters along geographic boundaries [19].
We also performed analysis of SNPs from genes involved in an endogenous pathway, which
has been under evolutionary pressure. Using ten genes involved in insulin signaling, we
obtained individual genotypes for 172 tagSNPs and performed hierarchical clustering. Using
SNP genotypes for insulin-signaling pathway genes containing polymorphisms, the YRI
individuals clearly separated from the individuals in the three other populations (Figure 1C).
The rest of the three populations were interspersed, although a majority of the CEU individuals
tended to cluster together. As with the drug pathways, PCA analysis showed no clear racial
differences across PC#1, accounting for 35% of the variance (Figure 2C). PC#2, accounting
for 14% of the variance in the data, separated the YRI individuals from the other three
populations. As with the 5-FU pathway PCA, plotting individuals across PC#2 and PC#3 (7%
of variance) separated the YRI individuals from the other three populations, while also tending
to separate the CEU individuals from the mixture of JPT/CHB individuals (Figure 2G).
Discussion
The completion of the Human Genome Project was supposed to lead to an era of personalized
medicine, where patients would be treated with medications based on their individual genotype.
Although progress has been made in identifying gene polymorphisms that influence the
response to several drugs, the promise of personalized medicine has not been realized as of yet
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because personal genotyping is cost prohibitive and most drug-genotype interactions remain
unknown. Since individual causative alleles usually have distinct frequencies across the `Old
World' populations, there is potential utility in using race labels as a surrogate for genetic
information, as a means to the ultimate goal of individualized therapy.
Examples of individuals of different races having different responses to cancer chemotherapy
treatment have been well documented. A recent study reported that African-American patients
with stage III colon cancer had a lower 5-year survival rate than their non-Hispanic white
counterparts, when treated with a 5-FU-based therapy [20]. A pharmacokinetic study
demonstrated that clearance of tegafur, a 5-FU derivative, as part of the S-1 formulation (tegafur
plus potassium oxonate and gimeracil) was faster in Western (European and American) cancer
patients than in Japanese patients [21]. By contrast, a separate report found that 31 out of 45
(68.9%) American colorectal cancer patients suffered from diarrhea on uracil/tegafur (UFT)
plus leuvocorin (LV), compared with only 17 out of 44 (38.6%) Japanese patients (p = 0.006),
although both groups exhibited similar pharmacokinetics in processing tegafur [22]. The
discrepancy between the studies with regard to tegafur processing in Western and Japanese
populations may be due to the other components of the formulations (S-1 vs UFT/LV) affecting
metabolism of tegafur. Distinct responses have also been oberseved towards other cancer
chemotherapeutics. Non-small-cell lung cancer patients of Asian ancestry were found to have
a significantly improved response rate to docetaxel and carboplatin when compared with
Caucasians [23].
The results from our hierarchical clustering and PCA of the irinotecan, 5-FU and insulin
signaling pathways demonstrated that race is not a robust predictor of the genetic subgroups
within the human population. Clustering individuals across gene SNPs from the irinotecan
pathway (which do not interact with one another in the absence of drug) yielded very little
grouping by race, indicating that individuals within a racial group display heterogenous
genotypes for genes in the irinotecan pathway. Clustering individuals across SNPs from the 5-
FU pathway (which consists of a mixture of genes involved solely in drug metabolism and
genes involved in endogenous pyrimidine metabolism), showed that the majority of YRI
individuals grouped together, and possibly indicated more genotype homogeneity within these
individuals. Examination of the clustering based on insulin-signaling SNPs (consisting
exclusively of genes involved in endogenous biological processes), found even greater
clustering by racial group, with all of the YRI in a separate subcluster. The other individuals
tended to be grouped in relatively larger racial blocks than the other two pathways, which were
interspersed with one another.
We acknowledge that this study has limitations. Variability in response to drug therapies
between populations probably is not solely due to SNP differences. Most drug interactions are
polygenic, indicating that multiple genetic variants may act together to influence drug response.
Other factors, such as diet or other cultural practices, likely play equally significant roles.
Ideally, a large-scale clinical study of the interactions between drug treatments and race, among
different global populations, should be conducted to answer the fundamental question of how
to provide the best medical care to every individual. However, it is not feasible to do such a
study. Thus, we sought to identify an alternative method, using the data that is readily available
from the HapMap website. We attempted to determine whether the methodology of using
tagSNP genetic markers from well-defined drug pathways to separate samples from self-
identified racial groups was viable. Because this method is relatively inexpensive and easy to
perform, it has great potential benefit for future studies, as additional drug pathways are
elucidated and more SNPs are associated with response to treatment. Our results clearly
demonstrate that racial generalizations for treatment recommendations are not valid and are
consistent with other recent publications regarding the suitability of using patient race to
determine medical treatment [24,25].
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• Human genomic variants that affect patient response to drugs have been identified.
However, it remains unfeasible to individually genotype all patients prior to drug
treatment.
• Genomic SNP data for 270 individuals from four racial groups is available in the
online HapMap database.
• Using HapMap SNP data, the ability of race to be substituted for individual
genotyping, with regards to predicting the presence of drug-relevant genetic
markers, was determined. SNPs were selected from genes located in irinotecan
and 5-fluorouracil drug pathways.
Methods
• Hierarchical clustering and principal component analysis were performed to
analyze the data.
Results
• The majority of genomic heterogeneity in pharmacologic genes was determined
to be due to individual variation rather than racial grouping. Thus, race should not
be used as a predictive substitute for individual patient genotyping.
Conclusion
Our results indicate that the heterogeneity in genotypes in individuals from the examined racial
groups (YRI, CHB, JPT and CEU) increases, going from a totally endogenous biological
pathway to a totally exogenous pathway. However, it should be noted, that even for the insulin-
signaling pathway, which exhibited the least variability among individuals in a racial group,
race contributed only a small percentage to the variance across individuals. Since only a small
percentage of the variance of the two-drug pathway genotypes across individuals is accounted
for by race, the use of race as a substitute for genotyping would not appear to be clinically
beneficial. Therefore, until the knowledge surrounding the interactions of race, genotype and
drug response improves, individual genotyping of patients for known drug-influencing
polymorphisms is the best course for optimizing drug treatment.
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Figure 1. Hierarchical clustering of 270 HapMap individuals across SNPs
(A) irinotecan, (B) 5-FU, and (C) insulin pathway genes, and (D) 362 randomly chosen SNPs.
Racial groupings are indicated in the dendrogram. Full clustering figures are available in
Supplemental Figure 2 available online [108].
YRI: Yoruba from Ibadan; JPT: Japanese from Tokyo; CHB: Han Chinese from Beijing;
CEU: CEPH Caucasian.
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Figure 2. Principal components analysis of the 270 HapMap individuals
PC#1 (A-D) and PC#2 versus PC#3 (E-H) across SNPs from (A, E) irinotecan, (B, F) 5-FU,
and (C, G) insulin pathway genes and (D, H) 362 randomly chosen SNPs. Full PCA figures
are available in Figure 2 of the Supplemental material available at [108].
PC: Principal component; PCA: Principal components analysis.
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